

January 20, 2025^(Revised)

Narayana Hrudayalaya Limited: Ratings reaffirmed and assigned; rated amount enhanced

Summary of rating action

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Long-term - Term loans	617.00	1,714.00	[ICRA]AA (Stable); Reaffirmed & Assigned for enhanced amount
Short-term - Non-fund based	45.00	45.00	[ICRA]A1+; Reaffirmed
Long-term/ Short-term - Unallocated	1,058.00	1,956.00	[ICRA]AA (Stable)/ [ICRA]A1+; Reaffirmed & Assigned for enhanced amount
Long-term/ Short-term - Working capital	80.00	80.00	[ICRA]AA (Stable)/ [ICRA]A1+; Reaffirmed
Non-fund based - Working capital (sublimit)#	(90.00)	(90.00)	[ICRA]AA (Stable)/ [ICRA]A1+; Reaffirmed
Long-term – Fund based CC	100.00	100.00	[ICRA]AA (Stable); Reaffirmed
Non-convertible debenture	300.00	300.00	[ICRA]AA (Stable); Reaffirmed
Non-convertible debenture	-	1,000.00	[ICRA]AA (Stable); Assigned
Total	2,200.00	5,195.00	

*Instrument details are provided in Annexure-I; # Sub-limit of Fund-based – Working Capital

Rationale

The reaffirmation of ratings for Narayana Hrudayalaya Limited (NHL/the Group) continues to consider NHL's established position in the healthcare sector and the significant brand equity of Narayana Health. The ratings also derive comfort from the geographically diversified presence of the Group across India as well as its diversified operational specialities including cardiac care, renal sciences, oncology, neurosciences, orthopaedics and gastroenterology.

ICRA has also factored in NHL's strong financial profile while reaffirming the ratings. In FY2024 and H1 FY2025, NHL witnessed a YoY revenue growth of ~10.8% and ~8.0%, respectively supported by a steady increase in its ARPOB¹, sequentially increasing occupancy, improvement in the payor mix and improvement in performance of its new hospitals. NHL's Cayman operations registered a YoY revenue growth of ~12.8% in FY2024, driven by an increase in patient footfall and operationalisation of the new radiation oncology block in May 2023. In H1 FY2025, NHL's revenues from its Cayman operations remained largely flat due to the combined effect of transitioning to the new hospital and the general slowdown in local market. However, the performance is expected to be back into the positive trajectory in the upcoming quarters.

NHL's operating profit margin (OPM) improved to 23.0% in FY2024 from 21.6% in FY2023. This improvement was driven by increased throughput, digitisation, better case and payor mix, ramp-up in high value elective procedures, and various efficiency measures undertaken by the company. However, the OPM declined marginally to 22.3% in H1 FY2025 due to the muted performance of Cayman Islands. In FY2024 and H1 FY2025, NHL's debt coverage indicators moderated, with interest coverage at 11.9 times and 8.9 times, respectively, compared to 14.1 times in FY2023. Additionally, the total debt/OPBDITA ratio stood at 1.5 times as of March 31, 2024, and 1.4 times as of September 30, 2024, compared to 1.0 times as of March 31, 2023 on account of the ongoing partially debt-funded capex. NHL's liquidity profile remained strong, marked by cash and cash

¹ Average revenue per occupied bed

equivalents of ~Rs. 1,102.4 crore as of September 30, 2024. This was supported by significant undrawn credit lines and financial flexibility to avail additional limits.

The ratings are, however, constrained by NHL's high reliance on three flagship hospitals in India and the Cayman Islands for revenue and profit generation. Nonetheless, ICRA notes that revenue and profit dependence on these three hospitals has sequentially moderated, with improved performance across its other hospitals. Most Indian hospitals have now broken even and started contributing to profits. Further, in line with other industry players, NHL's performance remains exposed to the risk of adverse regulatory measures.

The Group has started investing aggressively in capacity expansion and plans to incur capex of Rs. 1,400-1,600 crore in FY2025. Between FY2026 and FY2029, NHL is expected to continue to incur sizeable capex towards commencement of construction of its new greenfield projects in Kolkata and Bengaluru. The capex is expected to be funded through a mix of debt and internal accruals. Given the sizeable planned capex, the Group's debt metrics are expected to witness some moderation in the near term. However, given the Group's strong earnings capability, debt metrics are expected to remain healthy despite the likely incremental debt to be availed.

The Group has a track record of growing and diversifying through strategic acquisitions. Any significant debt-funded acquisition, impacting the company's credit metrics, remains an event risk and would be evaluated on a case-by-case basis.

NHL has also ventured into the primary healthcare and wellness segment, combined with the insurance sector, through its two wholly-owned subsidiaries – NH Integrated Care Private Limited (NHIC) and Narayana Health Insurance Limited (NHIL). NHIC operates on a subscription-based model, provides an end-to-end integrated health care, primary care experience to its customers. NHIL provides a comprehensive health insurance plan combined with an integrated care program. Both the initiatives are currently in their nascent stages. Being in the investment phase, the company plans to incur a capital expenditure of Rs. 25-30 crore each fiscal on these initiatives. In H1 FY2025, NHL recorded a cash burn of approximately Rs. 50 crore (including capex) towards NHIC and NHIL and is expected to witness a similar cash burn in H2 FY2025. Going forward, the quantum of investments and the amount of cash burn in these new ventures will be monitored.

The Stable outlook on the long-term rating reflects ICRA's expectations that NHL will continue to benefit from its strong market position, investments in technology and ramp-up of operations at new hospitals, thereby, supporting the Group's credit profile.

Key rating drivers and their description

Credit strengths

Healthy market position with focus on affordability for patients – NHL enjoys a strong market position in the healthcare services industry as an established brand, especially in the cardiac and renal sciences. It has been expanding its core specialty areas to include oncology, neurology and neurosurgery, orthopedics, and gastroenterology. NHL has developed comprehensive cancer care services at multiple locations like Bengaluru, Mysore, Delhi, Gurugram, Jaipur, Katra, Howrah, and Raipur. Its goodwill and focus on patient affordability helped it in partnering with Government bodies, not-for-profit trusts and charities, and private organisations to operate and manage their healthcare facilities. Dr. Devi Prasad Shetty, Chairman of Narayana Health, has extensive experience of more than three decades and has received several awards such as the Padma Shri and Padma Bhushan for his contributions to affordable healthcare.

Geographically diversified operations with presence all over India – NHL has a network of 40 healthcare facilities (~5,789 operational beds) as on September 30, 2024, of which 19 hospitals (5,551 beds) are owned/operated, two (128 beds) are heart centres, 18 (no beds) are primary healthcare facilities including clinics and dialysis centre and one (110 beds) hospital is in the Cayman Islands. The company has a strong brand recognition in Karnataka and eastern India, with an emerging presence in western, central and northern India. NHL also has an international presence with the establishment of Health City Cayman Islands (HCCI) in North America. HCCI is in the process of commencing operations at an additional multi-specialty ~50-bed hospital, providing tertiary, critical care, and day-care services, with focus on outpatient services. Despite some moderation in margins during the ramp-up phase of the new hospital, HCCI is expected to further strengthen its operations in the Cayman Islands.

Strong financial profile – NHL witnessed a 10.8% and 8.0% revenue growth in FY2024 and H1 FY2025, respectively, on a YoY basis. This growth was supported by a steady improvement in its ARPOB, sequentially increasing occupancy, improvement in the payor mix and steady improvement in performance of the relatively new hospitals. However, growth in H1 FY2025 was impacted to a certain extent due to decline in footfall from international patients, which experienced a ~19% YoY reduction due to a sharp fall in patients from Bangladesh, owing to the geopolitical situation. NHL's OPM improved to 23.0% in FY2024 and 22.3% in H1 FY2025 from 21.6% in FY2023 on the back of growth across hospitals, including both flagship and new units. Key factors supporting margins included increased throughput, reduced consumption costs, better case and payor mix, healthy ramp-up in high-value elective procedures, and various efficiency measures undertaken by the company. The OPM for H1 FY2025 was also supported by reduction in international footfall, which in turn has improved the payor mix, as majority of the patients coming from Bangladesh are offered services at a discounted rate, given their economic status. However, the margin slightly declined due to muted performance in Cayman Islands. Further, the Group's cash, cash equivalents and liquid investments increased to Rs. 1,102.4 crore as on September 30, 2024, from Rs. and Rs. 1,103.5 crore as on March 31, 2024, compared to Rs. 406.1 crore as on March 31, 2023. The company's financial profile is expected to remain strong with the planned capex.

Credit challenges

High dependence on top three hospitals and the Cayman Island facility – A significant portion of NHL's consolidated revenue and operating profit is derived from the three best-performing hospitals of the Group in India, Narayana Institute of Cardiac Sciences, Mazumdar Shaw Medical Centre (both in Bengaluru) and Rabindranath Tagore International Institute of Cardiac Sciences (Kolkata), as well as the Cayman unit. In H1 FY2025, a sizeable portion of the consolidated revenues and operating profit was contributed by the top three hospitals in India. While NHL is largely dependent on the performance of these flagship facilities, the dependence has reduced significantly over the last few years.

Significant debt-funded capex plans – NHL has a planned capital outlay of Rs. 1,400-1,600 crore for FY2025 and is also expected to incur sizeable capex from FY2026 to FY2029, which will be funded partially through debt. Around Rs. 275 crore of capex outflow for FY2025 will be utilised towards completion of the greenfield multi-specialty hospital in Cayman Islands, which has started its out-patient operations in the last week of October 2024. While it is expected to help diversify its offerings in the Cayman Islands and provide a significant location-specific advantage to NHL, the overall consolidated margins may be impacted in the initial few quarters of operations. The capex for FY2026 to FY2029 includes replacement and maintenance capex of around Rs. 300-350 crore per year along with Rs. 900-1,200 crore per year for brownfield and greenfield expansion. The company is planning to add ~2,000 new beds in the upcoming 4 to 5 years, which will require an investment of Rs.4,000-5,000 crore. Most of these bed additions will be through greenfield projects while some will be through O&M model. The company is currently focused on setting up two greenfield facilities, one in Kolkata (~350 new beds in the first phase) and the other one in Bengaluru (~220 new beds). Both the units are expected to start operations by FY2029. Debt metrics of the company are expected to slightly moderate over the next few years with an expected increase in debt levels for partially funding the aforesaid capex. However, given the Group's strong earnings capability, the debt metrics are expected to remain healthy despite the incremental debt, which is expected to be availed.

Exposure to regulatory risks – Regulatory risks pertaining to restrictive pricing regulations levied by the Central and state government organisations could constrain the company's profit margins.

Environmental and social risks

Environmental considerations – As the company is a healthcare service provider, it does not manufacture any product and has limited environmental risks. However, it has taken significant steps towards the conservation of water and energy resources. At a Group level, 26% of the energy requirement is met from captive wind and hydro energy. For hospitals in Karnataka, 85-90% of the energy requirement is fulfilled by renewable sources. Overall, with multiple initiatives, the company has been able to reduce energy consumption by ~14.0% and its CO₂ footprint by around 14,963 tonnes in FY2024. Besides, as

a part of its water conservation initiatives, domestic wastewater from hospitals is treated in on-site wastewater treatment plants and reused so that more than 95% of the wastewater is recycled across NHL.

Social considerations – Exposure to social risks is moderate for NHL. These risks include litigation exposure and compliance with standard requirements, given the importance of the services provided. Further, regulatory interventions such as price control measures and the imposition of specific restrictions, if any, could impact the earnings of the company as well as the broader industry. NHL provides treatment to patients from economically weaker sections, supported by concessions and contributions from philanthropists and charitable institutions. Further, NHL has a very strong program for training Doctors and Nurses as well as a program called Udaan that provides NEET Education to under privileged children. NHL also provides educational fees support to students studying medicine and nursing and also supports feeding and wash programs in schools.

Liquidity position: Adequate

The Group’s operational cash inflows over the next twelve months, existing cash and liquid investments and ease of access to external financing, if required, are expected to be adequate to cover the operational expenses, planned capital expenditure and debt servicing obligations over this period. Further, the Group has a total working capital facility of around Rs. 234 crore, which remained unutilised in H1 FY2025. The Group has sizeable capex plans over the next 2-3 years. It is expected to raise incremental debt to partially fund the same. The company had free cash, bank balance and liquid investments of Rs. 1,102.4 crore as on September 30, 2024. Repayment on the existing debt stands at Rs. ~147.7 crore in FY2025, Rs. ~793.7 crore in FY2026 and Rs. ~419.4 crore in FY2027. ICRA expects the Group to meet its near-term and medium-term commitments through internal cash sources and incremental debt.

Rating sensitivities

Positive factors – A significant improvement in earnings, debt metrics and liquidity position, supported by a healthy ramp-up of new units, resulting in reduced dependence on the flagship hospital units, may result in a long-term rating upgrade.

Negative factors – Pressure on the ratings may emerge in case of a material deterioration in profitability and debt metrics of the company on account of sustained delay in achieving profitability at the new units. Specific credit metrics, which could lead to ratings downgrade include net debt / OPBITDA of more than 1.5 times on a sustained basis.

Analytical approach

Analytical Approach	Comments
Applicable rating methodologies	Corporate Credit Rating Methodology Hospitals
Parent/Group support	Not Applicable
Consolidation/Standalone	For arriving at the ratings, ICRA has considered the consolidated financials of NHL along with its operational subsidiaries and associate companies (mentioned in Annexure-2) on account of the strong business and financial linkages among these entities.

About the company

NHL operates a chain of multispecialty, tertiary and primary healthcare facilities. Dr. Devi Shetty, who has over 30 years of medical experience, incorporated NHL in 2000. The Group, which initially focused on cardiac and renal sciences, expanded to additional areas of focus such as cancer care, neurology, neurosurgery, orthopedics, and gastroenterology and was rebranded as ‘Narayana Health’ in 2013 to reflect the diversified presence. The Group owns and operates certain hospitals and enters into management agreements with hospitals under which the Group acquires operating control. As on September 30, 2024, it

had 40 healthcare facilities (5,789 operational beds) of which 19 hospitals (5,551 beds) are owned/operated, two (128 beds) are heart centres, 18 (no beds) are primary healthcare facilities including clinics and dialysis centre and one (110 beds) hospital is in the Cayman Islands. NHL has a strong presence in Karnataka and eastern India, with an emerging presence in western, central and northern India. The Narayana Health brand is associated with the delivery of affordable healthcare services by leveraging its economies of scale.

Key financial indicators (Audited)

NHL Consolidated	FY2023	FY2024	H1 FY2025
Operating income	4,529.7	5,018.4	2,741.0
PAT	606.8	789.6	400.3
OPBDIT/OI	21.6%	23.0%	22.3%
PAT/OI	13.4%	15.7%	14.6%
Total outside liabilities/Tangible net worth (times)	0.9	0.9	0.9
Total debt/OPBDIT (times)	1.0	1.5	1.4
Interest coverage (times)	14.1	11.9	8.9

Source: Company, ICRA Research; All ratios as per ICRA's calculations; Amount in Rs. crore ; PAT: Profit after tax; OPBDIT: Operating profit before depreciation, interest, taxes and amortisation

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

Instrument	Current rating (FY2025)			Chronology of rating history for the past 3 years					
	Type	FY2025		FY2024		FY2023		FY2022	
		Amount Rated (Rs Crore)	20-JAN-2025	Date	Rating	Date	Rating	Date	Rating
Long term / short term-unallocated-unallocated	Long Term/ Short Term	1,956.00	[ICRA]AA (Stable)/ [ICRA]A1+	02-FEB-2024	[ICRA]AA (Stable)/ [ICRA]A1+	25-APR-2022	[ICRA]AA- (Positive)/ [ICRA]A1+	15-APR-2021	[ICRA]AA- (Stable)/ [ICRA]A1+
			-	-	-	06-MAR-2023	[ICRA]AA (Stable)/ [ICRA]A1+	-	-
Long term / short term-others-fund based/non fund based	Long Term/ Short Term	80.00	[ICRA]AA (Stable)/ [ICRA]A1+	02-FEB-2024	[ICRA]AA (Stable)/ [ICRA]A1+	25-APR-2022	[ICRA]AA- (Positive)/ [ICRA]A1+	15-APR-2021	[ICRA]AA- (Stable)/ [ICRA]A1+
			-	-	-	06-MAR-2023	[ICRA]AA (Stable)/ [ICRA]A1+	-	-
Bonds/ncd/ltd	Long Term	1,000.00	[ICRA]AA (Stable)	-	-	-	-	-	-
Bonds/ncd/ltd	Long Term	300.00	[ICRA]AA (Stable)	02-FEB-2024	[ICRA]AA (Stable)	-	-	-	-
Short term-others-non fund based	Short Term	45.00	[ICRA]A1+	02-FEB-2024	[ICRA]A1+	25-APR-2022	[ICRA]A1+	15-APR-2021	[ICRA]A1+

			-	-	-	06-MAR-2023	[ICRA]A1+	-	-
Long term / short term-others-interchangeable	Long Term/ Short Term	(90.00)	[ICRA]AA (Stable)/ [ICRA]A1+	02-FEB-2024	[ICRA]AA (Stable)/ [ICRA]A1+	25-APR-2022	[ICRA]AA-(Positive)/ [ICRA]A1+	15-APR-2021	[ICRA]AA-(Stable)/ [ICRA]A1+
			-	-	-	06-MAR-2023	[ICRA]AA (Stable)/ [ICRA]A1+	-	-
Long term-term loan-fund based	Long Term	1714.00	[ICRA]AA (Stable)	02-FEB-2024	[ICRA]AA (Stable)	25-APR-2022	[ICRA]AA-(Positive)	15-APR-2021	[ICRA]AA-(Stable)
			-	-	-	06-MAR-2023	[ICRA]AA (Stable)	-	-
Long term-cash credit-fund based	Long Term	100.00	[ICRA]AA (Stable)	02-FEB-2024	[ICRA]AA (Stable)	25-APR-2022	[ICRA]AA-(Positive)	15-APR-2021	[ICRA]AA-(Stable)
			-	-	-	06-MAR-2023	[ICRA]AA (Stable)	-	-

Complexity level of the rated instrument

Instrument	Complexity Indicator
Long term- Term loan	Simple
Short term- Non-fund Based	Very Simple
Long term/ Short term- Unallocated	NA
Long term/ Short term- Working capital	Simple
Non-Fund based- Working capital (sublimit)	Very Simple
Long term – Fund based CC	Simple
Non-convertible debenture	Simple
Non-convertible debenture	Simple

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analyzing an entity's financial, business, industry risks or complexity related to the structural, transactional, or legal aspects. Details on the complexity levels of the instruments, is available on ICRA's website: [Click Here](#)

Annexure-I: Instrument details

ISIN	Instrument Name	Date of Issuance	Coupon Rate	Maturity	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Long Term- Term Loan	FY2018	NA	FY2029	1,714.00	[ICRA]AA (Stable)
NA	Short Term- Non-fund Based	NA	NA	NA	45.00	[ICRA]A1+
NA	Long Term/ Short Term Unallocated	NA	NA	NA	1,956.00	[ICRA]AA (Stable)/ [ICRA]A1+
NA	Long Term/ Short Term Working Capital	NA	NA	NA	80.00	[ICRA]AA (Stable)/ [ICRA]A1+
NA	Non-Fund Based- Working Capital (sublimit)	NA	NA	NA	(90.00)	[ICRA]AA (Stable)/ [ICRA]A1+
NA	Fund based - Cash Credit	NA	NA	NA	100.00	[ICRA]AA (Stable)
INE410P08016	Non-convertible debenture	Mar-19-2024	8.25%	Mar-19-2029	300.00	[ICRA]AA (Stable)
Yet to be placed	Non-convertible debenture	NA	NA	NA	1,000.00	[ICRA]AA (Stable)

Source: Company

[Please click here to view details of lender-wise facilities rated by ICRA](#)

Annexure II: List of entities considered for consolidated analysis

Company Name	NHL Ownership	Consolidation Approach
Narayana Hrudayalaya Surgical Hospital Pvt Ltd	100%	Full Consolidation
Meridian Medical Research and Hospital Ltd	99.13%	Full Consolidation
Narayana Hospitals Pvt Ltd	100%	Full Consolidation
Narayana Vaishno Devi Speciality Hospitals Pvt Ltd	100%	Full Consolidation
NH Integrated Care Private Limited	100%	Full Consolidation
Athma Healthtech Private Limited	100%	Full Consolidation
Health City Cayman Islands Ltd (HCCI)	100%	Full Consolidation
ENT in Cayman Ltd.	100%	Full Consolidation
Cayman Integrated Healthcare Limited	100%	Full Consolidation
NH Health Bangladesh private Limited	100%	Full Consolidation
Narayana Holdings Private Limited	100%	Full Consolidation
Narayana Health North America LLC	100%	Full Consolidation
Reya health Inc (formerly Cura Technologies Inc.)	43.58%	Full Consolidation
Medha AI Private Limited	100%	Full Consolidation
Narayana health Insurance Limited (NHIL)	100%	Full Consolidation
Samyat Healthcare Private Limited (SHPL)	100%	Full Consolidation
ISO Healthcare	0.00%	Full Consolidation

Source: Company data; As on March 31, 2024

Corrigendum

Rationale dated January 20, 2025, has been corrected with revisions as detailed below:

Format for date in Annexure-1 for one of the instruments has been updated.

ANALYST CONTACTS

Shamsher Dewan
+91 124 4545 328
shamsherd@icraindia.com

Kinjal Shah
+91 22 6114 3442
kinjal.shah@icraindia.com

Mythri Macherla
+91 22 6114 3435
mythri.macherla@icraindia.com

Piyush Kedar
+91 22 6114 3469
piyush.kedar@icraindia.com

RELATIONSHIP CONTACT

L. Shivakumar
+91 22 6114 3406
shivakumar@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani
Tel: +91 124 4545 860
communications@icraindia.com

Helpline for business queries

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)
info@icraindia.com

About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited




Registered Office

B-710, Statesman House 148, Barakhamba Road, New Delhi-110001

Tel: +91 11 23357940-45



Branches



© Copyright, 2025 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.